GAITHERSBURG, Md., June 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN ) today announced that data on its Acuitas ® AMR Gene Panel u5.47 (RUO) and Acuitas Lighthouse ® Knowledgebase will be presented at ASM Microbe 2018 being held June 7-11, 2018 in Atlanta. OpGen’s Senior Vice President of Research and Development, Terry Walker, Ph.D., will present the following:
| Poster title: | Semi-Quantitative Molecular Detection of 5 Bacterial Pathogens and 47 Antibiotic Resistance Genes in Urine Specimens and Culture Isolates (#369) | |
| Date and time: | Saturday, June 9, 11:00 a.m. – 1:00 p.m. ET | |
| Location: | Exhibit and Poster Hall, Building B, Halls B2-B5 | |
| Electronic Version: | Friday, June 8, 11:00 a.m. – 12:00 p.m. ET |
Additionally, OpGen will sponsor a symposium at 6:00 p.m. ET on June 8th, titled “Rapid Pathogen Detection and Prediction of Antimicrobial Resistance in Urinary Tract Infections.” The event will be held in Room B204, Georgia World Congress Center and will include presentations by:
- Stefan Riedel, M.D., Ph.D ., Associate Medical Director of the Clinical Microbiology Laboratories at Beth Israel Deaconess Medical Center and Associate Professor of Pathology at Harvard Medical School, titled “The Clinical Implications of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance”
- Donna Wolk, MHA, Ph.D . of Geisinger Medical Laboratories and Director of the Infectious Disease Research Laboratory at the Weis Research Center, titled “Impact of Rapid Syndromic Diagnostics to Clinical Workflow”
- Terry Walker, Ph.D. , Senior Vice President of Research & Development at OpGen, titled “OpGen Acuitas AMR Gene Panel u5.47 (RUO) and Acuitas Lighthouse: A Rapid Molecular Syndromic Test and Knowledgebase to Determine Pathogens and Predict Antibiotic Resistance in Complicated Urinary Tract Infection Specimens”
This symposium is neither sponsored nor endorsed by the American Society for Microbiology.
Additional data presented at the conference by independent researchers and OpGen on the Company’s rapid genetic testing and identification of antibiotic-resistant bacterial strains in U.S. and South American hospital systems include:
| Poster title: | Impact of Using a Rapid Diagnostic Test for the Identification and Treatment of Bacteremia and Fungemia in Four Colombian Hospitals’ Intensive Care Unit (#277) | |
| Presenter: | C. Hernandez-Gomez (El Bosque University) | |
| Date and time: | Friday, June 8, 11:00 a.m. – 1:00 p.m. ET | |
| Location: | Exhibit and Poster Hall, Building B, Halls B2-B5 | |
| Poster Title: | Prevalence and Distribution of 46 Antibiotic Resistance Genes in Pseudomonas Aeruginosa across Three Tertiary Care Hospitals (#337) | |
| Presenter: | S. Condon (Northwell Health) | |
| Date and time: | Saturday, June 9, 11:00 a.m. – 1:00 p.m. ET | |
| Location: | Exhibit and Poster Hall, Building B, Halls B2-B5 | |
| Poster title: | Predicting Carbapenem Resistance in Pseudomonas Aeruginosa through Whole Genome Sequencing Analysis (#471) | |
| Presenter: | W. Chang, Ph.D. (OpGen) | |
| Date and time: | Friday, June 8, 11:00 a.m. – 1:00 p.m. ET | |
| Location: | Exhibit and Poster Hall, Building B, Halls B2-B5 |
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. For more information, please visit www.opgen.com .
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.
The Acuitas AMR Gene Panel u5.47 (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures.
Forward-Looking Statements
This press release includes statements relating to OpGen’s Acuitas AMR Gene Panel u5.47 and Acuitas Lighthouse Software products in development. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen Contact: Michael Farmer Vice President, Marketing (240) 813-1284 mfarmer@opgen.com InvestorRelations@opgen.com
Investor Contacts: LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com
